Skip to content

Staar Surgical STAA Inventory write-downs

Inventory write-downs at other companies

Glaukos logo
GlaukosGKOS
$661.25K-40.5%

Other financials

Income statement

See full
Revenue$93.5M+120%
Gross profit$68.9M+146%
Operating income$8.0M+114%
Net income$5.2M+110%
EPS (diluted)$0.10+109%

Balance sheet

See full
Cash & equivalents$131.9M-23.8%
Total debt$37.3M+1.7%
Total equity$352.4M+0.7%
Total assets$451.1M-1.4%

Cash flow

See full
Operating cash flow-$21.7M-278%
CapEx$443.0K-69.8%
Free cash flow-$22.1M-207%

Valuation

See full
Market cap$1.44B+77.9%
Enterprise value$1.35B+100.0%
P/S+2.1×

Profitability

See full
Gross margin76.9%+2.9pp
Operating margin-9.1%-3.5pp
Net margin-7.2%-3.0pp
FCF margin-19.6%+55.9pp

Returns & leverage

See full
Return on equity-6%-2.4pp
Debt / equity0.1×0.0×
Current ratio5.1×+0.3×

Where this comes from

Reported directly by Staar Surgical in its filing.

Tagged under the XBRL concept us-gaap:InventoryWriteDown.

The official record: Staar Surgical’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Staar Surgical's inventory write-downs.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Staar Surgical's inventory write-downs?
Staar Surgical (STAA) reported inventory write-downs of $1.58M in Q1 2026.
How has Staar Surgical's inventory write-downs changed year-over-year?
Staar Surgical's inventory write-downs decreased by 22.5% year-over-year, from $2.03M to $1.58M.
What is the long-term trend for Staar Surgical's inventory write-downs?
Over 4 years (2021 to 2025), Staar Surgical's inventory write-downs has grown at a 34.0% compound annual growth rate (CAGR), from $1.65M to $5.33M.
What does inventory write-downs mean?
This represents the non-cash charge taken when the carrying value of inventory exceeds its net realizable value due to obsolescence, damage, or market price declines. It serves as a key indicator of inventory management quality and product demand health. High or frequent write-downs may signal inefficiencies in supply chain planning or declining product relevance.